Pacira’s Exparel Problems: CR Letter Stops New Indication
This article was originally published in The Pink Sheet Daily
FDA finds issues with a supplemental application to use the pain treatment for nerve block shortly after Pacira gives 2015 financial guidance.
You may also be interested in...
Pacira believes new clinical trial of post-surgical pain medication will satisfy FDA concerns raised in complete response letter for its supplemental NDA.
Keeping Track: Another Gene Therapy Approval, Several Priority Review Designations, And Many Resubmissions
The latest drug development news and highlights from our US FDA Performance Tracker.
Vaccines and Related Biological Products Advisory Committee also said that more data is needed to determine the groups that potentially could receive more than one periodic vaccine booster.